Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-08-04
- Last Posted Date
- 2019-05-31
- Lead Sponsor
- GE Healthcare
- Target Recruit Count
- 251
- Registration Number
- NCT00126412
- Locations
- 🇺🇸
GE Healthcare, Princeton, New Jersey, United States
Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-08-04
- Last Posted Date
- 2016-12-13
- Lead Sponsor
- GE Healthcare
- Target Recruit Count
- 587
- Registration Number
- NCT00126425
- Locations
- 🇺🇸
GE Healthcare, Princeton, New Jersey, United States
Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-08-04
- Last Posted Date
- 2018-03-14
- Lead Sponsor
- GE Healthcare
- Target Recruit Count
- 515
- Registration Number
- NCT00126438
- Locations
- 🇺🇸
GE Healthcare, Princeton, New Jersey, United States
© Copyright 2024. All Rights Reserved by MedPath